Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic β cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by tolerogenic antigen presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells which have demonstrated efficacy in NOD mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing β cell from endogenous progenitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationTHE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113 · cited 2×
“Although both humoral and cell-mediated immune mechanisms are active during diabetes, CD4+ T cells occupy a critical role in T1D pathology (Anderson and Bluestone, 2005), as exemplified by the observation that the majority of the genes associated with elevated disease risk relate to the function of…”
BackgroundInsulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093 · cited 1×
“Other assays have identified antigen-specific cells in the circulation (Pinkse et al., 2005).”
BackgroundEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668 · cited 1×
“…subsequent DPT-1 tested the efficacy of oral insulin in 388 prediabetic patients who were first- and seconddegree relatives of T1D patients and were also classified as at increased risk for developing T1D by genetic, immunological, and metabolic staging (Skyler et al., 2005; Sosenko et al., 2006).”
BackgroundThe NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588 · cited 1×
“…the critical role of adaptive immune responses in disease pathogenesis as well as identifying various targets that prevent diabetogenic autoimmune responses as prime therapeutic 488 Immunity 32, April 23, 2010 ª2010 Elsevier Inc. candidates (Atkinson and Leiter, 1999; Shoda et al., 2005).”
BackgroundVoltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simões, B. P., et al. (2007) · JAMA · doi:10.1001/jama.297.14.1568 · Cited by 573 · cited 1×
“Development of T1D is genetically controlled and thought to be initiated in susceptible individuals by environmental factors such as virus infections, although a viral cause has not been clearly identified (von Herrath, 2009).”
BackgroundGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520 · cited 1×
“The second trial used the 20 mg dosing regimen in recent-onset T1D children between 10 and 18 years of age (Ludvigsson et al., 2008).”
MethodConcannon, P., Rich, S. S., & Nepom, G. T. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0808284 · Cited by 510 · cited 1×
“…role in T1D pathology (Anderson and Bluestone, 2005), as exemplified by the observation that the majority of the genes associated with elevated disease risk relate to the function of CD4+ Th cells (e.g., a trio of major histocompatibility complex class II [MHC II] alleles [Concannon et al., 2009]).”
BackgroundPalmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationCouri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Kent, S. C., Chen, Y., Bregoli, L., Clemmings, S. M., Kenyon, N. S., Ricordi, C., Hering, B. J., & Hafler, D. A. (2005) · Nature · doi:10.1038/nature03625 · Cited by 409
Näntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382 · cited 1×
“…with genetic and immunological risks for developing T1D showed that nasal insulin administration at 1 unit/kg/day initiated soon after detection of autoantibodies had no beneficial effect on dia- 492 Immunity 32, April 23, 2010 ª2010 Elsevier Inc. betes prevention (Näntö-Salonen et al., 2008).”
BackgroundClinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes
Agardh, C.-D., Cilio, C. M., Lethagen, Å., Lynch, K., Leslie, R. D. G., Palmér, M., Harris, R. A., Robertson, J. A., & Lernmark, Å. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.12.003 · Cited by 226 · cited 3×
“A phase II safety and dose-finding trial conducted in patients with latent autoimmune diabetes in adults (LADA) (Agardh et al., 2005) showed the drug to be safe, and administration of two 20 mg subcutaneous doses 1 month apart led to an increase of fasting and stimulated C-peptide at 24 weeks compared to baseline, a b…”
BackgroundInfluentialSherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 1×
“For example, the combination of a glucagon-like peptide 1 (GLP-1) receptor agonist (Exendin-4) was found to augment b cell function in diabetic mice treated with anti-CD3 mAb or ATG (Ogawa et al., 2004; Sherry et al., 2007).”
BackgroundSelf-citationDimorphic histopathology of long-standing childhood-onset diabetes
Gianani, R., Campbell-Thompson, M., Sarkar, S. A., Wasserfall, C., Pugliese, A., Solis, J. M., Kent, S. C., Hering, B. J., West, E., Steck, A., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1642-y · Cited by 158
Cited by
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493
Self-citationGetts, D. R., Martin, A. J., McCarthy, D. P., Terry, R. L., Hunter, Z. N., Yap, W. T., Getts, M. T., Pleiss, M., Luo, X., King, N. J., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2434 · Cited by 392
Self-citationWherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Self-citationHunter, Z., McCarthy, D. P., Yap, W. T., Harp, C. T., Getts, D. R., Shea, L. D., & Miller, S. D. (2014) · ACS Nano · doi:10.1021/nn405033r · Cited by 301
Self-citation
Metadata
- Authors
- Luo, X., Herold, K. C., & Miller, S. D.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 32
- Issue
- 4
- Pages
- 488-499
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2097222424
- Cited by
- 136
- References
- 19
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.